Rinvoq Lq is a drug owned by Abbvie Inc. It is protected by 9 US drug patents filed in 2024 out of which none have expired yet. Rinvoq Lq's patents have been open to challenges since 17 August, 2023. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 17, 2036. Details of Rinvoq Lq's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US8962629 | Tricyclic compounds |
Jan, 2031
(6 years from now) | Active |
| USRE47221 | Tricyclic compounds |
Aug, 2033
(8 years from now) | Active |
| US10981923 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | Active |
| US11680069 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | Active |
| US9951080 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | Active |
| US11718627 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | Active |
| US11661425 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | Active |
| US11773105 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | Active |
| US11186584 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | Active |
FDA has granted several exclusivities to Rinvoq Lq. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Rinvoq Lq, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Rinvoq Lq.
Exclusivity Information
Rinvoq Lq holds 3 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Rinvoq Lq's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Product(NP) | Apr 26, 2027 |
| Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Several oppositions have been filed on Rinvoq Lq's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Rinvoq Lq's generic, the next section provides detailed information on ongoing and past EP oppositions related to Rinvoq Lq patents.
Rinvoq Lq's Oppositions Filed in EPO
Rinvoq Lq has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 16, 2018, by Generics (U.K.) Limited. This opposition was filed on patent number EP10835061A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP10835061A | Feb, 2018 | Generics (U.K.) Limited | Opposition rejected |
US patents provide insights into the exclusivity only within the United States, but Rinvoq Lq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Rinvoq Lq's family patents as well as insights into ongoing legal events on those patents.
Rinvoq Lq's Family Patents
Try Our Curated Drug Screens
Generic Launch
Generic Release Date:
Rinvoq Lq's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 17, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rinvoq Lq Generics:
There are no approved generic versions for Rinvoq Lq as of now.
Rinvoq Lq Competitors
Understanding your competition is essential for market success. There are several other brand drugs using the same active ingredient (Upadacitinib) as Rinvoq Lq. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
|
About Rinvoq Lq
Rinvoq Lq is a drug owned by Abbvie Inc. Rinvoq Lq uses Upadacitinib as an active ingredient. Rinvoq Lq was launched by Abbvie in 2024.
Approval Date:
Rinvoq Lq was approved by FDA for market use on 26 April, 2024.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Rinvoq Lq is 26 April, 2024, its NCE-1 date is estimated to be 17 August, 2023.
Active Ingredient:
Rinvoq Lq uses Upadacitinib as the active ingredient. Check out other Drugs and Companies using Upadacitinib ingredient
Dosage:
Rinvoq Lq is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1MG/ML | SOLUTION | Prescription | ORAL |